In Wednesday’s Wall Street session, Summit Therapeutics Inc (NASDAQ:SMMT) shares traded at $24.74, up 7.61% from the previous session.
SMMT stock price is now 8.79% away from the 50-day moving average and 18.41% away from the 200-day moving average. The market capitalization of the company currently stands at $18.37B.
With the price target of $30, UBS recently initiated with Buy rating for Summit Therapeutics Inc (NASDAQ: SMMT). On June 11, 2025, Leerink Partners recently initiated its ‘Underperform’ rating on the stock quoting a target price of $12, while ‘Citigroup’ rates the stock as ‘Buy’
A total of 84.99% of the company’s stock is owned by insiders.
During the past 12 months, Summit Therapeutics Inc has had a low of $7.41 and a high of $36.91. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 10.63, and a quick ratio of 10.63. The fifty day moving average price for SMMT is $22.741 and a two-hundred day moving average price translates $20.89265 for the stock.
The latest earnings results from Summit Therapeutics Inc (NASDAQ: SMMT) was released for 2025-03-31. The company reported revenue of $66.85 million for the quarter, compared to $42.39 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 57.71 percent.
